145 related articles for article (PubMed ID: 18848145)
1. Interpretation of amino-terminal pro-brain natriuretic peptide levels in the HPS and the CORONA study.
Cleland JG; Squire I; Ng L
J Am Coll Cardiol; 2008 Sep; 52(13):1104-5. PubMed ID: 18848145
[No Abstract] [Full Text] [Related]
2. Can natriuretic peptides help identify heart failure patients for whom statins are beneficial?
Daniels LB; Barrett-Connor E
J Am Coll Cardiol; 2009 Nov; 54(20):1860-1. PubMed ID: 19892236
[No Abstract] [Full Text] [Related]
3. Rosuvastatin and cardiovascular continuum when time is important.
Barrios V; Escobar C
J Am Coll Cardiol; 2010 Apr; 55(15):1645-6; author reply 1646. PubMed ID: 20378088
[No Abstract] [Full Text] [Related]
4. Statins and heart failure.
Athyros VG; Karagiannis A; Mikhailidis DP
J Am Coll Cardiol; 2010 Apr; 55(15):1644-5; author reply 1646. PubMed ID: 20378087
[No Abstract] [Full Text] [Related]
5. Evolution of amino-terminal pro-B type natriuretic peptide testing in heart failure.
Januzzi JL; Bayes-Genis A
Drug News Perspect; 2009 Jun; 22(5):267-73. PubMed ID: 19609464
[TBL] [Abstract][Full Text] [Related]
6. Amino-terminal pro-brain natriuretic peptide to diagnose congestive heart failure in patients with impaired kidney function.
Lamb EJ; Vickery S; Price CP
J Am Coll Cardiol; 2006 Sep; 48(5):1060-1; author reply 1061. PubMed ID: 16949506
[No Abstract] [Full Text] [Related]
7. Natriuretic peptide-guided therapy for heart failure: ready for "battle" or too "scarred" by the challenges of trial design?
Maisel A
J Am Coll Cardiol; 2009 Dec; 55(1):61-4. PubMed ID: 20117365
[No Abstract] [Full Text] [Related]
8. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
[TBL] [Abstract][Full Text] [Related]
9. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of N-terminal pro-brain natriuretic peptide.
Zhang XY; Zhu JH
Chin Med J (Engl); 2004 Nov; 117(11):1716-22. PubMed ID: 15569492
[No Abstract] [Full Text] [Related]
11. Response to "Getting the right message".
Januzzi JL; Camargo CA; Tung R
Ann Emerg Med; 2007 Mar; 49(3):381-3; discussion 383; author reply 384. PubMed ID: 17317512
[No Abstract] [Full Text] [Related]
12. [N-terminal peptide pro-BNP and endothelin in haemodialysis patients].
Racek J
Vnitr Lek; 2007 Nov; 53(11):1139-41. PubMed ID: 18277620
[No Abstract] [Full Text] [Related]
13. Biomarker-guided treatment of heart failure: still waiting for a definitive answer.
Troughton RW; Frampton CM; Nicholls MG
J Am Coll Cardiol; 2010 Dec; 56(25):2101-4. PubMed ID: 21144970
[No Abstract] [Full Text] [Related]
14. Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting.
Green SM; Green JA; Januzzi JL
Am J Ther; 2009; 16(2):171-7. PubMed ID: 19300043
[TBL] [Abstract][Full Text] [Related]
15. Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.
Ding LG; Hua W; Zhang S; Chu JM; Chen KP; Wang Y; Wang FZ; Chen X
Chin Med J (Engl); 2009 Mar; 122(6):617-21. PubMed ID: 19323922
[TBL] [Abstract][Full Text] [Related]
16. Cardiac resynchronization therapy and B-type natriuretic peptide in heart failure.
Huang DJ
Chin Med J (Engl); 2009 Mar; 122(6):608-9. PubMed ID: 19323919
[No Abstract] [Full Text] [Related]
17. [TOPCAT study. Heart failure: spironolactone disappoints in the "problem patient"].
Overbeck P
MMW Fortschr Med; 2013 Dec; 155(21-22):26. PubMed ID: 24724258
[No Abstract] [Full Text] [Related]
18. Q: Should target natriuretic peptide levels be used for outpatient management of chronic heart failure?
Ibrahim A; Baibars M; Alraies MC; Oliveira GH
Cleve Clin J Med; 2012 Jan; 79(1):22-5. PubMed ID: 22219230
[No Abstract] [Full Text] [Related]
19. Brain natriuretic peptide is unchanged after 4 weeks of continuous positive airway pressure therapy.
Pepperell J; Stradling J; Davies R
J Sleep Res; 2006 Dec; 15(4):463-4. PubMed ID: 17118104
[No Abstract] [Full Text] [Related]
20. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial.
Shah MR; Claise KA; Bowers MT; Bhapkar M; Little J; Nohria A; Gaulden LH; McKee VK; Cozart KL; Mancinelli KL; Daniels H; Kinard T; Stevenson LW; Mancini DM; O'Connor CM; Califf RM
Am Heart J; 2005 Nov; 150(5):893-8. PubMed ID: 16290955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
